Product
RTA 402
Aliases
RTA 402 (Bardoxolone Methyl), RTA 402 Dose1, RTA 402 Dose2
3 clinical trials
3 indications
Indication
Diabetic NephropathyIndication
MelanomaIndication
Liver DiseaseClinical trial
An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic NephropathyStatus: Completed, Estimated PCD: 2009-05-31
Clinical trial
A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 in Patients With Advanced Malignant MelanomaStatus:
Clinical trial
Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 (CDDO-Me) Administered Orally for 14 Days in Patients With Hepatic DysfunctionStatus: Terminated, Estimated PCD: 2007-11-30